The Celiac Disease Unit Recognition Program (CDURP) recognizes units that demonstrate commitment to delivering quality celiac disease diagnosis and treatment.

    Learn More

  • SSCD leaders and members networking to build a better society.

  • SSCD has worked to develop a statement regarding the use of oats in products that are identified as gluten-free

  • Read SSCD's statement on the use of low gluten wafers (pub.8/17)

Latest News

Please join us for the Annual Business Meeting and General Assembly on Monday, May 8, 2023 at the Hyatt Regency McCormick Place in Chicago 
The Society for the Study of Celiac Disease Annual Meeting and General Assembly will be taking place on Monday, May 8, 2023 at 6:30pm at the Hyatt Regency McCormick Place Hotel in room Burnham ABC. The newly elected officers will be announced at this meeting. Immediately following the meeting, the Celiac Disease Foundation will have a program and reception. Heavy Hors D' oeuvre and beverages will be served. All active members are invited for these two events.

Did you Miss the February 16, 2023 webinar on the Review of New ACG Celiac Guidelines? 
Click here to view the recording.

Did you Miss the November 16, 2022 Best of the 19th International Celiac Disease Symposium? 
Click here to view the recording.

Did you Miss the SSCD Webinar Food Insecurity in Celiac Disease? 
Click here to view the recording.

Did you Miss the SSCD Webinar Food Insecurity in Celiac Disease? 
Click here to view the recording.

Did you Miss Session Four of the SSCD Clinical Trial Series? 
Click here to view the recording.

Did you Miss Session Three of the SSCD Clinical Trial Series? 
Click here to view the recording.

Did you Miss Session Two of the SSCD Clinical Trial Series? 
Click here to view the recording.

Did you Miss Session One of the SSCD Clinical Trial Series? 
Click here to view the recording.

Update on Celiac Disease
The SSCD CDURP member Celiac Center of Excellence Hartford Healthcare Connecticut GI PC has shared with volume one of their Update on Celiac Disease. Click here to read more.

Four-Part Clinical Trial Webinar Series
Given the maturing state of the celiac disease clinical trial landscape there is an increased need for sites who are prepared to participate in celiac disease clinical trials. Learn More here.

Did you miss the April 13, 2022 webinar: Let's Talk About Oats?
SSCD members can view the recording here.

SSCD - Conference Travel Grant
SSCD is offering a $1,000 grant to support trainees with travel and/or accommodation to present celiac-related research at national and international conferences. Click Here for elgibility and to apply.

Did you miss the January 26, 2022 webinar: Non-Responsive Celiac Disease?
SSCD members can view the recording here.

Early Career Research Award
We are excited to inform you of this new funding opportunity, a joint initiative by Beyond Celiac and the Society for the Study of Celiac Disease. This early career research award for SSCD members covers up to $90,000 per year for 2 years. The application is due February 28, 2022. Details regarding this funding opportunity are provided here

The double-edged sword of gut bacteria in celiac disease andimplications for therapeutic potential

Heather J. Galipeau and Elena F. Verdu 

Celiac disease (CeD) is an immune-mediated disease, triggered by gluten ingestion, in genetically susceptible individuals. Thegluten-free diet (GFD) is the only current treatment for CeD, but is difficult to follow, has high non-adherence rates, and does notalways lead to symptomatic or mucosal remission. Microbially-mediated mechanisms have been proposed to contribute to diseasepathogenesis, and clinical studies support an association, but mechanistic insight has been difficult to obtain. Recent advancesusing translational approaches have provided clues to the mechanisms through which bacteria could contribute to CeDpathogenesis. In this review we discuss these bacterially mediated mechanisms, which include the modulation of pathogenic orprotective pathways. Targeting these pathways through microbial therapeutics could provide adjuvant therapies to the GFD. Click here to read more.

Society for the Study of Celiac Disease Statement on COVID-19 Vaccines and Children
With the news that the Food and Drug Administration (FDA) and Centers for Disease Control (CDC) have authorized the Pfizer-BioNTech COVID-19 vaccine for those ages 5-11, we have received inquiries about the advisability of proceeding with vaccination in this age group. We fully agree with the CDC recommendation that everyone ages 5 and older get a COVID-19 vaccine to help protect against COVID-19. This includes individuals with celiac disease. Click here to read more

Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease
Progress has been made in understanding coeliac disease, a relatively frequent and underappreciated immune- mediated condition that occurs in genetically predisposed individuals. However, several gaps remain in knowledge related to diagnosis and management. The gluten- free diet, currently the only available management, is not curative or universally effective (some adherent patients have ongoing duodenal injury). Unprecedented numbers of emerging therapies, including some with novel tolerogenic mechanisms, are currently being investigated in clinical trials. In March 2020, the Celiac Disease Foundation and the Society for the Study of Celiac Disease convened a consensus workshop to identify high- yield areas of research that should be prioritized. Workshop participants included leading experts in clinical practice, academia, government and pharmaceutical development, as well as representatives from patient support groups in North America. This Roadmap summarizes key advances in the field of coeliac disease and provides information on important discussions from the consensus approach to address gaps and opportunities related to the pathogenesis, diagnosis and management of coeliac disease. The morbidity of coeliac disease is often underestimated, which has led to an unmet need to improve the management of these patients. Expanded research funding is needed as coeliac disease is a potentially curable disease. Read the full article

SSCD Statement on Covid-19 Vaccination 

With the recent news that the Food and Drug Administration has granted Emergency Use Authorization for a vaccine against SARS-CoV-2, the virus that causes Covid-19, patients with celiac disease are asking for guidance about the advisability of this and other Covid-19 vaccines in the context of celiac disease, an immune-mediated condition. As scientists and clinicians who care for people with celiac disease, we urge people with celiac disease to receive a Covid-19 vaccine that has met government regulatory approval.
Click here to read more.

Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation

The advantage of a high-tryptophan diet
Although 40% of the worldwide population express celiac disease susceptibility genes, only 1% will develop the disorder, suggesting a role for environmental factors, including the gut microbiota. Lamas et al. show that celiac disease is associated with an impaired capacity of the gut microbiota to metabolize tryptophan into aryl hydrocarbon receptor (AhR) ligands in patients with celiac disease. Gluten-induced immunopathology in mice expressing a celiac disease susceptibility gene was ameliorated after AhR pathway activation by a high-tryptophan diet, or by treatment with a pharmacological AhR agonist or bacteria producing AhR ligands. AhR pathway modulation by the gut microbiota may have potential as a therapeutic strategy for treating celiac disease.
Click here to read more.

Nanoparticles Show Promise as a Treatment for Celiac Disease
New study suggests gluten could be prevented from triggering the damaging immune reaction. A potential treatment for celiac disease in which nanoparticles act like a Trojan horse and carry a hidden component of gluten to reprogram the immune system not to react has shown positive early results in a new clinical trial. Click here for more.

Our members are keeping us in the loop
SSCD members continue to provide resources and information to help the GI community understand celiac disease.  Visit our Educational Resources CD Management section for links to interesting content.

Attention members: To access members-only sections of the website, please login.  If you do not recall your login credentials, please use the 'forgot password' function or contact SSCD at 630-522-7886 or info@theceliacsociety.org.

Please submit any announcements you wish to share to info@theceliacsociety.org.


View Calendar

Education & Events




SSCD appreciates the support of our corporate partners